New Study from UK's Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care
As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK's largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty.
Presented at the 2025 ADHD World Congress in Prague, Czech Republic, the findings highlight the role of QbCheck, Qbtech's remote testing solution, in enabling clinicians to make more confident, data-informed decisions, supporting a more personalized and collaborative care model. The tool allows for greater clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and helping to improve alignment between clinicians and patients throughout the care journey.
The results from ADHD 360's implementation of this model showcase how a standardized approach to virtual ADHD care improves clinician confidence, reduces wait times, and enhances patient engagement. In addition to its use as a diagnostic tool, QbCheck, the remote objective assessment tool from Qbtech, was used to monitor treatment effects, helping clinicians adjust treatment as needed.
'Consistency and quality are at the heart of our virtual care model, and QbCheck plays a key role in upholding these standards,' says Carl Ellis, Mental Health Nurse and Team Manager, ADHD 360. 'The objective data it provides ensures that every patient is assessed using the same evidence-based criteria, regardless of where they are. Not only does this minimize the risk of subjective bias, but it also ensures that our clinical team can deliver reliable, high-quality care at scale.'
The results showed significant improvement from the baseline to post-treatment assessments. Beyond QbCheck's value as an objective symptom measurement and diagnostic tool, the data highlights patient response to pharmacological treatment, which can support clinicians in developing individualized and adaptive treatment plans, providing quantifiable data on symptom presentation and response.
In this study, data was collected from routine QbCheck assessments completed as part of the ADHD 360 model in the United Kingdom. Baseline data was collected prior to diagnosis and treatment, with additional QbCheck assessments administered after patients were optimized with stimulant medication treatment. In addition to QbCheck, all patients were given the Adult ADHD Self Report Scale (ASRS) or the Swanson, Nolan and Pelham Rating Scale (SNAP) and QbCheck Rating Scale (QbRS) to assess self-reported symptoms.
'QbCheck brings transparency and structure to the process, enabling clinicians to clearly visualize symptoms, track treatment response, and give patients the objective validation they deserve,' says Dr. Mikkel Hansen, Chief Medical Officer, Qbtech. 'This data shows how a standardized pathway to virtual ADHD care helps clinicians successfully facilitate remote monitoring of medication treatment effects, symptom regulation, and overall treatment outcomes, which are essential to virtual care models like ADHD 360.'
With increased scrutiny around ADHD care and virtual care models expanding, QbCheck stands out for its clinical rigor, patient-centered design and scalability. First developed in 2016, QbCheck enriches the clinician and patient experience to ensure optimal care in virtual settings. QbCheck is used by more than 10,000 clinicians worldwide operating virtual clinics and those with brick-and-mortar locations who offer remote ADHD services. Its flexibility for these clinicians and their patients is key to providing equitable access to care regardless of location, especially those who live in a mental health provider shortage area.
Since its launch in Sweden in 2002, Qbtech has supported more than 1 million patients globally. More than 40 independent studies document the company's benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than standardized self-rating scales, and consistency of care across multiple disciplines.
Visit www.qbtech.com to learn more.
About Qbtech
Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit www.qbtech.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250510899654/en/
CONTACT: Media Contact:
Hilari Barton, Trevelino/Keller
[email protected]
404-214-0722 x 130
KEYWORD: NORTH AMERICA UNITED STATES UNITED KINGDOM EUROPE CZECH REPUBLIC TEXAS
INDUSTRY KEYWORD: TECHNOLOGY MENTAL HEALTH OTHER TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE OTHER HEALTH HEALTH GENERAL HEALTH DATA MANAGEMENT
SOURCE: Qbtech
Copyright Business Wire 2025.
PUB: 05/10/2025 06:45 AM/DISC: 05/10/2025 06:46 AM
http://www.businesswire.com/news/home/20250510899654/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda
The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges include high therapy costs and resistance to current treatments. Major players investing in R&D include Novartis, Abbvie, and Bristol-Myers Squibb. Key terms: Global Multiple Myeloma Market, Multiple Myeloma Growth, Targeted Therapies, Immunotherapies, Market Expansion. Multiple Myeloma Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Global Multiple Myeloma Market was valued at USD 21.78 billion in 2024 and is expected to reach USD 40.41 billion by the year 2033, at a CAGR of 7.11% during the forecast period from 2025 to 2033 The growth of the market is fueled by the increasing number of multiple myeloma cases, developments in targeted therapies, and the expanding use of immunotherapies. Increased oncology research, enhanced diagnostic methodologies, and the increasing availability of healthcare facilities are further adding to market growth. The therapies for multiple myeloma are chemotherapy, immunotherapy, target therapies, corticosteroids, and stem cell transplants. Increasing advancements in monoclonal antibodies and CAR-T cell therapy are enhancing outcomes among patients, and these therapies are becoming more popular globally. With increasing awareness of cancer and better diagnosis methods, multiple myeloma therapies are becoming increasingly popular in the U.S., Europe, and Asia-Pacific. Pharmaceutical industries are heavily investing in new drug development, and governments are also funding cancer research, further propelling treatment availability. Consequently, the multiple myeloma market continues to grow, bringing new hope to patients of Growth in the Multiple Myeloma Market Improvements in Targeted TherapiesThe emergence of targeted therapies like monoclonal antibodies and proteasome inhibitors has considerably enhanced treatment efficacy for multiple myeloma patients. These treatments have greater efficacy with less side effect than conventional chemotherapy. With continued research in immunotherapy and CAR-T cell therapy, more effective therapies are being made available, and patient survival is on the rise. Consequently, drug companies are investing heavily in drug development, further fueling market growth. Dec 2024, Merck reported that the FDA has accepted for filing the Biologics License Application for clesrovimab (MK-1654), a long-acting monoclonal antibody to help protect infants from RSV in their first RSV Prevalence of Multiple MyelomaThe worldwide prevalence of multiple myeloma is on the rise, especially among the elderly. Genetic susceptibility, exposure to toxic chemicals, and lifestyle changes are factors that lead to an increased incidence of the disease. As more and more cases are being diagnosed yearly, the need for effective treatment options is on the rise. This has driven governments and health organizations to invest more in multiple myeloma research and the availability of treatments, driving market growth. There were about 35,000 cases of MM in 2021 globally, with the most in China and Germany, with 47,003 and 32,010 cases, respectively. In 2021, Europe boasted the highest ASIR and ASPR, and North America the highest ASMR and Healthcare Spending and AwarenessRising healthcare spending in developed and emerging economies is contributing positively towards the multiple myeloma market. Governments and private bodies are initiating awareness campaigns and screening programs to encourage early detection and timely treatment. Patients now enjoy improved access to new therapies through reimbursement schemes and insurance coverage, also driving the adoption of treatments. With increasing numbers of hospitals and clinics incorporating advanced oncology treatments, the multiple myeloma market is set to see significant in the Multiple Myeloma Market Exorbitant Cost of TherapyImmunotherapies and targeted agents used in treating multiple myeloma are costly, hence unavailable to most patients, particularly those in developing areas. Bone marrow transplants and maintenance therapy costs further increase the burden. In spite of availability of reimbursement schemes in certain countries, affordability becomes a serious concern, limiting the growth of the Effects and Therapy ResistanceIn spite of the progress in treatment, patients tend to develop resistance to current therapies with time, which requires frequent modification of treatment regimens. Moreover, most therapies have serious side effects, such as infections, tiredness, and organ injury, which lower the quality of life for patients. These issues propel the necessity for ongoing research and innovation in treatment methods. Key Players Analyzed: Overview, Key Persons, Recent Developments, Product Portfolio, Revenue Novartis AG Abbvie Inc. Sanofi Johnson and Johnson Baxter International Inc. Pfizer Inc. Takeda Pharmaceutical Company Ltd Bristol-Myers Squibb Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $21.78 Billion Forecasted Market Value (USD) by 2033 $40.41 Billion Compound Annual Growth Rate 7.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Multiple Myeloma Market6. Market Share Analysis6.1 By Drugs Types6.2 By Disease Types6.3 By End User6.4 By Country7. Drugs Types7.1 Chemotherapy7.2 Protease Inhibitors7.3 Monoclonal Antibody7.4 Others8. Disease Types8.1 Active multiple myeloma8.2 Smoldering multiple myeloma9. End User9.1 Hospitals9.2 Clinics9.3 Others10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 United Arab Emirates11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Multiple Myeloma Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
an hour ago
- New York Times
Monica Seles interview: The tennis star's next reset after autoimmune diagnosis
For several years, one of the great champions of the modern era has existed as a kind of tennis ghost. Monica Seles won nine Grand Slam titles, seven of them before her 19th birthday. Tennis is a sport in which 'phenom' trips off the tongue with ease; Seles, with her two-handed groundstrokes on both wings and her ability to paint lines from anywhere, at any time, defined it. Seles spent 91 weeks in a row as world No. 1, playing 34 tournaments in that time. She reached the final in 33 of them. Advertisement In April of 1993, Seles and Steffi Graf were dueling for supremacy at the top of the sport when a fan fixated on Graf stabbed Seles at an event in Germany. She came back from over two years of physical and mental turmoil and promptly won two more Grand Slams, even as the place where she displayed her gifts to the world — the tennis court — lost its safety. Seles, in a word, reset, while carrying the weight of what had happened. She retired from tennis in 2008, continuing to play exhibitions alongside other luminaries, including John McEnroe and Chris Evert. She played regularly, mentoring younger players. But since 2019, the 51-year-old, born in Yugoslavia, has largely disappeared from public view. Around that year, Seles started experiencing double vision and extreme weakness in her arms and legs. She would see two balls coming at her on the tennis court instead of one. 'I thought, 'OK, just push through it,'' Seles said during a video interview from her home in Florida. 'But a couple of instances happened when — on court and in daily life — I realized there was something going on.' After a time, Seles sought medical advice, which was not easy to come by as 2019 turned into 2020 and the Covid-19 pandemic began. Her doctor referred her to a neurologist. After two years of tests and scans, she was diagnosed with Myasthenia Gravis (MG), a chronic autoimmune disease that affects 150 to 200 people per million worldwide. The immune system attacks the neuromuscular junction — the pathway through which nerves and muscles communicate. Its symptoms, which include the double vision and muscle weakness Seles experienced on and off the tennis court, can come in phases, making an accurate diagnosis hard to obtain. 'Patients can present with fatigue and then healthcare providers have no idea what to do with that,' Dr. Beth Stein, director of neuromuscular diseases at St. Joseph's Health in New Jersey, said in an interview. Advertisement What ensues is a kind of reverse scavenger hunt, where physicians conduct a series of tests that eliminate mortal threats such as brain tumors and motor neurone disease. Antibody tests can confirm MG, but some patients don't possess them. 'When I first got my diagnosis, I'd never heard of it in the news or from anybody else,' Seles said. For Seles, MG has brought on another reset — the process tennis players go through from point to point, game to game, set to set, and match to match throughout their careers. Her return to competitive tennis after her stabbing came at the 1995 Canadian Open. She won the title, losing 14 games en route. She lost a titanic U.S. Open final to Graf before resetting again to win the Australian Open in 1996. The process, in the micro and macro, defined her career and, to some extent, her life. 'After coming out from my former country to the IMG Academy, I had to totally reset,' she said. 'When I became No. 1, it was a huge reset because everybody treats you differently. Then obviously when I got stabbed, that was a huge reset. And then when I was diagnosed, it was a huge reset. 'The day-to-day part of managing it, depending on my symptoms, is really adjusting, you know. I think anybody else who has Myasthenia Gravis knows it's a continuous adjustment.' Some days, Seles can play tennis and pickleball and walk her dogs. She makes sure to play with people who understand what she is living with. Still, 'some days are very extreme,' Seles said. That can be hard to take for a world-class athlete. Sports are a part of her DNA, and Seles wondered who she would be if she weren't able to train and compete. Again, she drew on her experiences in tennis and some of the challenges she has faced in life. 'After my stabbing, I had to deal with that internally for quite a few years to process it and my MG diagnosis was kind of very similar,' she said. 'I had to understand my new normal of day-to-day life, what I can do work-wise and different things.' Advertisement Seles plans to attend the U.S. Open later this month to do an event to raise awareness about her condition. She will also catch some tennis while she is there. The sport remains a big part of her life and she follows it closely. During her interview, she was counting down the hours to the Canadian Open final featuring Victoria Mboko and Naomi Osaka, thinking through the storylines of a teen sensation taking on a four-time Grand Slam champion on a journey back toward the top of the sport. 'Women's tennis right now,' she said. 'None of us know who's going to win whatever tournament is up next, and that's great.' She was following Venus Williams' comeback particularly closely. The Wimbledon semifinal between Aryna Sabalenka and Amanda Anisimova had tantalized her, while her heart sank for Anisimova when Iga Świątek beat her 6-0, 6-0 in the final. 'Former players, you know, you've been on both sides of it,' she said. 'When I got bageled, I can remember those matches 30 years later, but also when I won my Grand Slams. As a former player, it's really interesting to watch it from that angle, let's say, as compared to, you know, when my mom watches it as a fan.' She'd like to do some television commentary. She's done some previously and loved it. 'I personally love listening to Chrissy (Evert), obviously, because she can cover so many different generations and the expertise,' Seles said. 'She has so much life experience, which I think for the younger generation is so important to hear.' Indeed, she does. Still, there may be no one in tennis who has more life experience than Seles. Spot the pattern. Connect the terms Find the hidden link between sports terms Play today's puzzle
Yahoo
an hour ago
- Yahoo
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Monica Seles - argenx 1 Monica Seles - argenx 2 Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the 'Go for Greater' MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced a partnership with nine-time Grand Slam tennis champion Monica Seles. For the first time ever, Seles is publicly speaking out about her experience with myasthenia gravis (MG) in support of argenx's Go for Greater initiative. The partnership aims to raise awareness and understanding of MG, and connect those affected with available tools and support resources. 'My MG journey over the past 5 years has not been an easy one. I felt isolated and defeated as many of the activities I enjoyed were no longer physically possible for me. I've since realized that by sharing my story, I can raise awareness of this disease, empower patients to advocate for themselves and help them connect with the MG community for support,' said Monica Seles. 'I am excited to partner with the argenx team – to inspire others living with MG to rally against this disease, pursue their goals, and live a fulfilling life. We're all in this together.' 'At argenx, we are committed to supporting the MG community by fostering understanding and connection,' said Karen Massey, Chief Operating Officer, argenx. 'We applaud Monica for sharing her personal story and are excited to collaborate with her to amplify the voices of MG patients and caregivers. Her journey and dedication to this cause will help people living with MG engage in meaningful conversations and build a supportive network around this challenging disease. Together, we hope to shine a light of understanding and support for those affected by MG.' argenx has a long-standing commitment to the MG community, helping to empower patients through programs such as Go for Greater. This program supports patients in achieving a greater quality of living by fostering connections between real people with MG, and offering support and helpful resources. In addition to the new partnership with Seles, argenx is a premier Global sponsor of the upcoming 2025 U.S. Open to amplify awareness of MG on a global stage. In the U.S., over 120,000 people are living with MG, an autoimmune, neuromuscular condition that causes a variety of symptoms, including weakness in the arms and legs, fatigue, difficulty walking, and blurred and double vision. For more information about the Go for Greater campaign, visit About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact: Media contact for argenx:Ben Petokbpetok@ Media contact for Real Chemistry: Ashley Cohen ascohen@ Attachments Monica Seles - argenx 1 Monica Seles - argenx 2Sign in to access your portfolio
